All In Biotech

Drug Trial Radar · NCT05647811

Study of NM8074 in Adult C3 Glomerulopathy Patients

A Phase Ib, Open Label, Dose Escalation Study of NM8074 in Subjects With C3 Glomerulopathy (C3G)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

May 2027

Primary completion

Aug 2029

Study completion Jul 2030

Sponsor

Lead sponsor
NovelMed TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.

Conditions

  • C3 Glomerulopathy

Interventions

  • NM8074Drug

    NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monitoring for incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
  2. Change from Baseline or Percent Change from Baseline in Urine Protein to Creatine Concentration Ratio (UPCR)Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
  3. Change from Baseline or Percent Change from Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR)Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
  4. Ratio to Baseline of UPCR and UACRTime frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3
  5. Change from Baseline or Percent Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.